Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.70
NUVA's Cash to Debt is ranked higher than
59% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. NUVA: 0.70 )
NUVA' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 0.7

Equity to Asset 0.49
NUVA's Equity to Asset is ranked higher than
57% of the 375 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. NUVA: 0.49 )
NUVA' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.93
Current: 0.49

0.36
0.93
Interest Coverage 1.22
NUVA's Interest Coverage is ranked lower than
61% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. NUVA: 1.22 )
NUVA' s 10-Year Interest Coverage Range
Min: 1.22   Max: 9999.99
Current: 1.22

1.22
9999.99
F-Score: 5
Z-Score: 2.43
M-Score: -2.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.53
NUVA's Operating margin (%) is ranked higher than
63% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. NUVA: 0.53 )
NUVA' s 10-Year Operating margin (%) Range
Min: -27436.54   Max: 6.71
Current: 0.53

-27436.54
6.71
Net-margin (%) -1.21
NUVA's Net-margin (%) is ranked higher than
62% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.13 vs. NUVA: -1.21 )
NUVA' s 10-Year Net-margin (%) Range
Min: -27211.54   Max: 16.37
Current: -1.21

-27211.54
16.37
ROE (%) -1.51
NUVA's ROE (%) is ranked higher than
63% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. NUVA: -1.51 )
NUVA' s 10-Year ROE (%) Range
Min: -322.04   Max: 21.43
Current: -1.51

-322.04
21.43
ROA (%) -0.75
NUVA's ROA (%) is ranked higher than
63% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. NUVA: -0.75 )
NUVA' s 10-Year ROA (%) Range
Min: -768.33   Max: 10.76
Current: -0.75

-768.33
10.76
ROC (Joel Greenblatt) (%) 1.27
NUVA's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.84 vs. NUVA: 1.27 )
NUVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -737.95   Max: 17.53
Current: 1.27

-737.95
17.53
Revenue Growth (%) 11.70
NUVA's Revenue Growth (%) is ranked higher than
87% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. NUVA: 11.70 )
NUVA' s 10-Year Revenue Growth (%) Range
Min: -40.2   Max: 486.2
Current: 11.7

-40.2
486.2
EBITDA Growth (%) 12.10
NUVA's EBITDA Growth (%) is ranked higher than
87% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -2.20 vs. NUVA: 12.10 )
NUVA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 22.7
Current: 12.1

0
22.7
EPS Growth (%) -53.80
NUVA's EPS Growth (%) is ranked lower than
51% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NUVA: -53.80 )
NUVA' s 10-Year EPS Growth (%) Range
Min: -66.3   Max: 31
Current: -53.8

-66.3
31
» NUVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NUVA Guru Trades in Q3 2013

Steven Cohen 578,930 sh (+59.99%)
Mario Gabelli 90,700 sh (+49.42%)
Jim Simons 227,788 sh (+34.56%)
PRIMECAP Management 914,000 sh (+11.18%)
Joel Greenblatt 68,823 sh (+2.58%)
Ken Fisher 379,650 sh (+0.73%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Paul Tudor Jones 18,600 sh (-91.05%)
» More
Q4 2013

NUVA Guru Trades in Q4 2013

Louis Moore Bacon 25,000 sh (New)
Mario Gabelli 115,700 sh (+27.56%)
Jim Simons 261,788 sh (+14.93%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
PRIMECAP Management 914,000 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 367,150 sh (-3.29%)
Steven Cohen 482,285 sh (-16.69%)
Paul Tudor Jones 11,600 sh (-37.63%)
» More
Q1 2014

NUVA Guru Trades in Q1 2014

Jim Simons 346,527 sh (+32.37%)
Mario Gabelli 125,700 sh (+8.64%)
PRIMECAP Management 914,000 sh (unchged)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 361,300 sh (-1.59%)
Steven Cohen 405,000 sh (-16.02%)
Paul Tudor Jones 8,800 sh (-24.14%)
» More
Q2 2014

NUVA Guru Trades in Q2 2014

Paul Tudor Jones 13,082 sh (+48.66%)
Mario Gabelli 155,700 sh (+23.87%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Steven Cohen 437,000 sh (unchged)
Jim Simons 344,488 sh (-0.59%)
PRIMECAP Management 906,000 sh (-0.88%)
Ken Fisher 336,395 sh (-6.89%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-06-30 Add 23.87%0.01%$32.26 - $39.25 $ 37.5510%155700
Joel Greenblatt 2013-12-31 Sold Out 0.06%$24.07 - $33.52 $ 37.5525%0
Mario Gabelli 2013-12-31 Add 27.56%$24.07 - $33.52 $ 37.5525%115700
Mario Gabelli 2013-09-30 Add 49.42%$22.82 - $26.99 $ 37.5553%90700
Joel Greenblatt 2013-06-30 Reduce -38.01%0.05%$19.93 - $24.79 $ 37.5572%67093
Mario Gabelli 2013-06-30 Add 32.82%$19.93 - $24.79 $ 37.5572%60700
Joel Greenblatt 2013-03-31 Add 37.81%0.03%$15.46 - $21.31 $ 37.55106%108240
Mario Gabelli 2013-03-31 Add 42.81%$15.46 - $21.31 $ 37.55106%45700
Joel Greenblatt 2012-12-31 New Buy0.07%$12.65 - $23.01 $ 37.55158%78542
PRIMECAP Management 2012-12-31 Add 34.88%$12.65 - $23.01 $ 37.55158%669000
Mario Gabelli 2012-12-31 Add 88.24%$12.65 - $23.01 $ 37.55158%32000
Mario Gabelli 2012-03-31 Add 21.43%$11.35 - $17.56 $ 37.55160%17000
Vanguard Health Care Fund 2011-06-30 Reduce -21.13%0.06%$24.98 - $34.65 $ 37.5522%1680103
Mario Gabelli 2011-06-30 Add 33.33%$24.98 - $34.65 $ 37.5522%12000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.82
NUVA's P/B is ranked higher than
74% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. NUVA: 2.82 )
NUVA' s 10-Year P/B Range
Min: 0.98   Max: 10.93
Current: 2.82

0.98
10.93
P/S 2.42
NUVA's P/S is ranked higher than
73% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. NUVA: 2.42 )
NUVA' s 10-Year P/S Range
Min: 0.86   Max: 10.64
Current: 2.42

0.86
10.64
PFCF 29.80
NUVA's PFCF is ranked higher than
86% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. NUVA: 29.80 )
NUVA' s 10-Year PFCF Range
Min: 6.98   Max: 188.94
Current: 29.8

6.98
188.94
EV-to-EBIT 488.00
NUVA's EV-to-EBIT is ranked higher than
67% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 38.19 vs. NUVA: 488.00 )
NUVA' s 10-Year EV-to-EBIT Range
Min: 20.9   Max: 484.8
Current: 488

20.9
484.8
Current Ratio 3.69
NUVA's Current Ratio is ranked higher than
79% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. NUVA: 3.69 )
NUVA' s 10-Year Current Ratio Range
Min: 1.58   Max: 15.05
Current: 3.69

1.58
15.05
Quick Ratio 2.70
NUVA's Quick Ratio is ranked higher than
78% of the 393 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. NUVA: 2.70 )
NUVA' s 10-Year Quick Ratio Range
Min: 1.14   Max: 13.9
Current: 2.7

1.14
13.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.49
NUVA's Price/Tangible Book is ranked higher than
73% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. NUVA: 4.49 )
NUVA' s 10-Year Price/Tangible Book Range
Min: 2.36   Max: 34.31
Current: 4.49

2.36
34.31
Price/DCF (Projected) 2.00
NUVA's Price/DCF (Projected) is ranked higher than
86% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 27.67 vs. NUVA: 2.00 )
NUVA' s 10-Year Price/DCF (Projected) Range
Min: 1.21   Max: 25.15
Current: 2

1.21
25.15
Price/Median PS Value 0.74
NUVA's Price/Median PS Value is ranked higher than
90% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.19 vs. NUVA: 0.74 )
NUVA' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 2.73
Current: 0.74

0.29
2.73
Earnings Yield (Greenblatt) 0.20
NUVA's Earnings Yield (Greenblatt) is ranked lower than
56% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. NUVA: 0.20 )
NUVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 4.8
Current: 0.2

0.2
4.8
Forward Rate of Return (Yacktman) 1.26
NUVA's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 1.19 vs. NUVA: 1.26 )
NUVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8   Max: 1.7
Current: 1.26

-8
1.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:NK8.Germany
Nuvasive Inc, was incorporated in Delaware in July 1997. The Company is a medical device company engaged in developing minimally disruptive surgical products and procedures for the spine. The Company's currently-marketed product portfolio is engaged in applications for spine fusion surgery, including biologics. The Company's main product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as an offering of biologics, cervical, motion preservation products, and Intra-Operative Monitoring (IOM) services. Its spine surgery product line offerings, which include products for the thoracolumbar spine, the cervical spine, and a set of motion preservation product offerings still under development, are mainly used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. Its biologic product line offerings include allograft, (donated human tissue) — Triad , and Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells, FormaGraft, a collagen synthetic product used to aid the fusion process, and AttraX, a synthetic bone graft material, which is still in the process of U.S. regulatory clearance, to aid in spinal fusion. Its MAS platform, with the unique advantages provided by its nerve monitoring systems, enables an innovative lateral procedure known as eXtreme Lateral Interbody Fusion, or XLIF, in which surgeons access the spine for a fusion procedure from the side of the patient's body, rather than from the front or back. Its MaXcess instruments provide access to the spine in a manner that affords direct visualization and its nerve monitoring systems allow surgeons to avoid critical nerves. Its cervical product offering now provides a full set of solutions for cervical fusion surgery, including allograft and CoRoent implants, as well as cervical plating and posterior fixation products, and a set of motion preservation product offerings still under development. The Company competes with Medtronic Sofamor Danek (Medtronic), Natus, Cadwell Laboratories, and VIASYS Healthcare, a division of CareFusion Corporation DePuy, Stryker Spine and Synthes, Inc. The Company's products,medical devices and tissues subject to regulation by the FDA and other regulatory bodies.
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure Apr 11 2013 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 2,015 Shares Jan 25 2011 
Weekly Guru Bargains Highlights: ASIA , SAY , VRX , AMLN , NUVA Jan 09 2011 
Weekly Guru Bargains Highlights: ASIA, SAY, VRX, AMLN, NUVA Jan 01 2011 
Three Stocks for 2011: NUVA, ENOC, CBK Nov 25 2010 
NuVasive Inc. Reports Operating Results (10-Q) Nov 05 2010 
NuVasive Inc. Reports Operating Results (10-Q) Aug 06 2010 
NuVasive Inc. (NUVA) CEO and Chairman Alexis V Lukianov sells 5,000 Shares Jul 12 2010 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 5,000 Shares Jun 22 2010 
NuVasive Inc. (NUVA) CEO and Chairman Alexis V Lukianov sells 7,500 Shares Jun 08 2010 


More From Other Websites
NuVasive Spine Foundation(TM) Exceeds $13 Million in Global Effort to Support Patients in Need Sep 08 2014
NuVasive(R) to Participate in Investor Events in August and September 2014 Aug 05 2014
NUVASIVE INC Financials Aug 05 2014
NUVASIVE INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 04 2014
Bob McNamara, the Executive Vice President and CFO of LDR Holding Corporation (LDRH), Interviews... Aug 01 2014
Will This Price Target Increase Help NuVasive (NUVA) Stock Today? Jul 30 2014
NuVasive Inc Earnings Call scheduled for 5:30 pm ET today Jul 29 2014
NUVASIVE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 29 2014
NuVasive Reports Second Quarter 2014 Financial Results and Increases Full Year Guidance Jul 29 2014
Q2 2014 NuVasive Jul 29 2014
NuVasive(R) Announces Conference Call and Webcast of Second Quarter 2014 Results Jul 15 2014
Insider Trading Alert - NUVA, TUES And KR Traded By Insiders Jul 14 2014
NuVasive(R) to Participate in the 21st Annual International Meeting on Advanced Spine Techniques... Jul 09 2014
NuVasive(R) Names Carol Cox Executive Vice President Strategy and Corporate Communications Jul 07 2014
Insider Trading Alert - CSC, NUVA And BAS Traded By Insiders Jul 03 2014
Will This Analyst Upgrade Help NuVasive (NUVA) Stock Today? Jun 26 2014
Insider Trading Alert - DVN, NUVA And SWN Traded By Insiders Jun 25 2014
NuVasive(R) Announces the Release of the Next Generation Monitoring Platform for Spine Surgery Jun 23 2014
NuVasive would have negative read through from Stryker deal, says RBC Capital May 29 2014
NuVasive management to meet with Piper Jaffray May 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK